{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/conjunctivitis-infective/prescribing-information/topical-chloramphenicol/","result":{"pageContext":{"chapter":{"id":"5c5a2718-f454-5220-81fd-c982d4420795","slug":"topical-chloramphenicol","fullItemName":"Topical chloramphenicol","depth":2,"htmlHeader":"<!-- begin field 43d7569d-0a4e-4f52-8354-098621e3d5ee --><h2>Topical chloramphenicol</h2><!-- end field 43d7569d-0a4e-4f52-8354-098621e3d5ee -->","summary":"","htmlStringContent":"<!-- begin item d49b0c19-d32d-4bda-8369-e8f6a74def38 --><!-- end item d49b0c19-d32d-4bda-8369-e8f6a74def38 -->","topic":{"id":"245d0a83-e460-5cf6-bb9f-5b290f285eb6","topicId":"ed2c519f-023f-46a3-983a-117707073336","topicName":"Conjunctivitis - infective","slug":"conjunctivitis-infective","lastRevised":"Last revised in April 2018","chapters":[{"id":"fbd71ba7-3d3f-51a3-a9dd-4b52e0a56009","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9e582b5b-cef7-5045-ac48-f2e16a0efce2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6ad803b-b834-514c-a66c-51db50d9bbea","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"dc7859c4-e24d-53f8-9ae8-3ef60935541d","slug":"changes","fullItemName":"Changes"},{"id":"00dc0d59-2f79-5889-8444-4824089eb72e","slug":"update","fullItemName":"Update"}]},{"id":"ea2edf68-d8e0-5937-90ff-ee564bb02527","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a34071e3-b1ed-5258-8e22-ae1bb85d5a3c","slug":"goals","fullItemName":"Goals"},{"id":"6a3dfcfe-0e37-5202-bef7-dd116ca18128","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9e9f3451-8747-5e06-91fa-c8523a7e68ba","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4883cd0c-a16c-59af-8b54-c6bd354f313d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f7f5987-b50c-55c3-8e5d-666cbe7c6d48","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"84242960-0415-55ac-a1c2-8b5adaab83f4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f008541b-b7be-5af3-8714-e8146300ff54","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f2e8a715-3f00-596d-8298-c250775f1fdb","slug":"definition","fullItemName":"Definition"},{"id":"dba4cb0f-b50c-512b-9e68-560be9ae7147","slug":"prevalence","fullItemName":"Prevalence"},{"id":"88ed8864-c0fc-510c-a4ec-438afedc7ced","slug":"causes","fullItemName":"Causes"},{"id":"3af23469-6316-5579-8439-affc8122afe4","slug":"complications","fullItemName":"Complications"},{"id":"f9f25145-3861-5ce7-b9aa-c90732e5def9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7d7962ba-c1ee-5e78-9ec8-f1803268d57b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4368df5f-6b2c-5ac2-8d9d-42a96bc19760","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"08d4c01c-039f-5999-a16c-aba6061abcd8","slug":"assessment","fullItemName":"Assessment"},{"id":"abd6f420-3a9f-5aa4-9c9d-cb8731b2c750","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"4f74d431-2e88-5b46-81f9-6459d459a761","fullItemName":"Management","slug":"management","subChapters":[{"id":"4ab0dfc8-5fff-5217-8bf6-5d0d5d842a1a","slug":"who-should-i-refer-to-ophthalmology","fullItemName":"Scenario: Who should I refer to ophthalmology?"},{"id":"b563c7fb-c61d-5f8d-9fea-cda5a3bc49ec","slug":"management-in-primary-care","fullItemName":"Scenario: Management in primary care"}]},{"id":"e288e22d-a343-590a-937c-923db47edf63","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5c5a2718-f454-5220-81fd-c982d4420795","slug":"topical-chloramphenicol","fullItemName":"Topical chloramphenicol"},{"id":"00fd3462-346a-502b-8017-1e1435b2c834","slug":"topical-fusidic-acid","fullItemName":"Topical fusidic acid"}]},{"id":"71c6ce21-1821-52a1-9051-9a9312261074","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f6c64841-06f4-529e-ab3c-b954aa2d45fa","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"518de4bc-ed53-5a8b-9936-01e04c351432","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"010e24d3-bdf1-5985-9e05-a9dd2c110ddb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a1eeb52c-83bb-5f24-a172-735272c3a89e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fcd4d626-0c82-5190-bf8f-a45ab99540a1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d7fa1f43-6726-5ef3-8d4e-bec8cdc717e5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d2966af5-8ae1-5551-a8da-9ca043c0ca3e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e288e22d-a343-590a-937c-923db47edf63","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"39a1636c-1010-5b28-9186-1474d4c4a503","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e95cf947-9d16-49ff-9eb8-919f4e35f04f --><h3>Contraindications and cautions</h3><!-- end field e95cf947-9d16-49ff-9eb8-919f4e35f04f -->","summary":"","htmlStringContent":"<!-- begin item 59936a71-5ce4-4fc0-92fa-fd37f5fe465f --><!-- begin field 0b740c3a-db70-4379-92e8-97131b9cebda --><ul><li>Do not prescribe topical chloramphenicol to people who:<ul><li>Are pregnant or breastfeeding.</li><li>hypersensitivity to the active substance or to any of the excipients.</li><li>Have had myelosuppresssion during previous exposure to chloramphenicol.</li><li>Have a personal or family history of blood dyscrasias including aplastic anaemia.</li></ul></li><li>Topical chloramphenicol should be not be used on a prolonged basis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-infective/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-infective/references/\">BNF 73, 2017</a>]</p><!-- end field 0b740c3a-db70-4379-92e8-97131b9cebda --><!-- end item 59936a71-5ce4-4fc0-92fa-fd37f5fe465f -->","subChapters":[]},{"id":"f070f295-c431-518e-9adb-1b858bdaf2e9","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ec106210-9e04-497b-a0d1-f8187f0b08bf --><h3>Adverse effects</h3><!-- end field ec106210-9e04-497b-a0d1-f8187f0b08bf -->","summary":"","htmlStringContent":"<!-- begin item 4781cea7-c6e0-4ac4-9269-215b51760b1a --><!-- begin field 4c8c5525-2985-4915-935c-4ebd8e7ac79a --><ul><li>Adverse effects are usually minor and include:<ul><li>Transient irritation, burning, stinging and sensitivity reactions such as itching and dermatitis.</li></ul></li><li>Rare more serious adverse effects may occur and include:<ul><li>Hypersensitivity reactions including angioedema, anaphylaxis, urticaria, fever, vesicular and maculopapular dermatitis.</li><li>Bone marrow depression and aplastic anaemia have been reported following topical use of chloramphenicol.<ul><li>The summary of product characteristics states that whilst the hazard is a rare one, it should be borne in mind.</li><li>The British National Formulary states that the recommendation that chloramphenicol eye drops should be avoided because of an increased risk of aplastic anaemia is not well founded.</li><li>Data from the International Granulocytosis and Aplastic Anaemia Study collected in Israel, Germany, Italy, Hungary, Bulgaria, Sweden and Thailand (n = 185 million person-years of observation) found that among 426 cases of aplastic anaemia there was no use of chloramphenicol eye drops. The authors concluded that although evidence of an association was found to be lacking, the prevalence of use among controls was low and the possibility of an increased risk could not be excluded [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-infective/references/\">Wiholm, 1998</a>].</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-infective/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-infective/references/\">BNF 73, 2017</a>]</p><!-- end field 4c8c5525-2985-4915-935c-4ebd8e7ac79a --><!-- end item 4781cea7-c6e0-4ac4-9269-215b51760b1a -->","subChapters":[]},{"id":"ca69c1e5-d27b-532e-83bd-3e487aa097fb","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field 8e71fa35-f1d3-4152-adf4-a76700cf6f7b --><h3>Drug interactions</h3><!-- end field 8e71fa35-f1d3-4152-adf4-a76700cf6f7b -->","summary":"","htmlStringContent":"<!-- begin item 001ba052-a3cb-4099-a2ea-a76700cf6dea --><!-- begin field d32ee0ab-08f1-4520-bf3e-a76700cf6f7b --><p><strong>Possible drug interactions include:</strong></p><ul><li>Other drugs liable to depress bone marrow function — concomitant administration should be avoided.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-infective/references/\">ABPI, 2017</a>]</p><!-- end field d32ee0ab-08f1-4520-bf3e-a76700cf6f7b --><!-- end item 001ba052-a3cb-4099-a2ea-a76700cf6dea -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}